Literature DB >> 21498912

Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease.

Haiqiong Huang1, Peng Zhang, Zhen Wang, Feng Tang, Zhen Jiang.   

Abstract

BACKGROUND: It is unclear why some patients, who undergo complete repair or palliative surgery for congenital heart disease (CHD), still develop irreversible pulmonary artery hypertension (PAH). There is no consensus to preoperationally assess the reversible and irreversible pulmonary vasculopathy seen in PAH. METHODS AND
RESULTS: The peri-operative pulmonary hemodynamic data of 16 CHD patients (reversible PAH, n = 6; irreversible PAH, n = 10) were analyzed. The lung biopsies were also performed during surgery for defining histopathological characteristics as well as immunohistochemical expression of endothelin-1 (ET-1), endothelin-1 receptors (ETR), and its downstream signaling markers in the small pulmonary arteries and arterioles. Neointimal formation and neoangiogenesis was characterized by increased intimal layer immunoreactivity for α-SMA, Factor VIII, CD34, and VEGF. Neointimal formation was found in 90% of patients and neoangiogenesis was found in 80% of patients with irreversible PAH. Neither was present in the reversible PAH group and the control group. Expression of ET-1 and ETR in the neointimal layer of the pulmonary arterioles was upregulated in irreversible PAH, and immunoreactivity of phospho-Akt, phospho-ERK1/2, and phospho-mTOR was also increased in irreversible PAH.
CONCLUSIONS: Increased expression of ET-1, ETR, and activation of signaling pathways were observed in the pulmonary arteries and arterioles of irreversible PAH patients associated with CHD. Activation of these pathways might in turn lead to neointimal formation and neoangiogenesis and thus might contribute to irreversible pulmonary vascular abnormalities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498912     DOI: 10.1253/circj.cj-10-0670

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  7 in total

1.  ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats.

Authors:  Gang Li; Yinglong Liu; Yaobin Zhu; Aijun Liu; Yulin Xu; Xiaofeng Li; Zhiqiang Li; Junwu Su; Lizhong Sun
Journal:  Lung       Date:  2013-05-08       Impact factor: 2.584

2.  Adenosine A2A receptor-dependent proliferation of pulmonary endothelial cells is mediated through calcium mobilization, PI3-kinase and ERK1/2 pathways.

Authors:  Aftab Ahmad; Jerome B Schaack; Carl W White; Shama Ahmad
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

3.  Characteristics of Pulmonary Vascular Remodeling in a Novel Model of Shunt-Associated Pulmonary Arterial Hypertension.

Authors:  Mingjie Zhang; Zhiyu Feng; Rui Huang; Chongrui Sun; Zhuoming Xu
Journal:  Med Sci Monit       Date:  2018-03-19

4.  Potential biomarkers and targets in reversibility of pulmonary arterial hypertension secondary to congenital heart disease: an explorative study.

Authors:  Li Huang; Li Li; Enci Hu; Guo Chen; Xianmin Meng; Changming Xiong; Jianguo He
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

Review 5.  Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases.

Authors:  Arun Samidurai; Rakesh C Kukreja; Anindita Das
Journal:  Oxid Med Cell Longev       Date:  2018-08-23       Impact factor: 6.543

6.  Transgelin as a potential target in the reversibility of pulmonary arterial hypertension secondary to congenital heart disease.

Authors:  Li Huang; Li Li; Tao Yang; Wen Li; Li Song; Xianmin Meng; Qing Gu; Changming Xiong; Jianguo He
Journal:  J Cell Mol Med       Date:  2018-10-18       Impact factor: 5.310

Review 7.  Notch3 signalling and vascular remodelling in pulmonary arterial hypertension.

Authors:  Hannah E Morris; Karla B Neves; Augusto C Montezano; Margaret R MacLean; Rhian M Touyz
Journal:  Clin Sci (Lond)       Date:  2019-12-20       Impact factor: 6.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.